Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Latest Biotechnology and Denali Therapeutics Inc., Maravai LifeSciences Holdings, Inc. Stock News

As of September 4, 2026, Denali Therapeutics Inc. had a $3.6 billion market capitalization, compared to the Biotechnology median of $282.4 million. Denali Therapeutics Inc.’s stock is up 34.9% in 2026, down 7.2% in the previous five trading days and up 50.64% in the past year.

Currently, Denali Therapeutics Inc. does not have a price-earnings ratio. Denali Therapeutics Inc.’s trailing 12-month revenue is $3.6 million with a % net profit margin. As of September 4, 2026, Denali Therapeutics Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-2.347 per share for the current fiscal year. Denali Therapeutics Inc. does not currently pay a dividend.

As of September 4, 2026, Maravai LifeSciences Holdings, Inc. had a $1.1 billion market cap, putting it in the 46th percentile of all stocks. Maravai LifeSciences Holdings, Inc.’s stock is up 125.2% in 2026, down 4.7% in the previous five trading days and up 210.17% in the past year.

Currently, Maravai LifeSciences Holdings, Inc. does not have a price-earnings ratio. Maravai LifeSciences Holdings, Inc.’s trailing 12-month revenue is $208.8 million with a -37.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $-0.181 per share for the current fiscal year. Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.

How We Compare Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Denali Therapeutics Inc.	DNLI	na
Maravai LifeSciences Holdings, Inc.	MRVI	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Denali Therapeutics Inc. does not have a meaningful Value Score. Maravai LifeSciences Holdings, Inc. has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to value.

Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. Growth Grades

Company	Ticker	Growth
Denali Therapeutics Inc.	DNLI	na
Maravai LifeSciences Holdings, Inc.	MRVI	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Denali Therapeutics Inc. does not have a meaningful Growth Score. Maravai LifeSciences Holdings, Inc. has a Growth Score of 8, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. is the better investment when it comes to sustainable growth.

Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Denali Therapeutics Inc.	DNLI	B
Maravai LifeSciences Holdings, Inc.	MRVI	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Denali Therapeutics Inc. has a Momentum Score of 75, which is Strong. Maravai LifeSciences Holdings, Inc. has a Momentum Score of 96, which is Very Strong.

The Momentum Grade Winner: Maravai LifeSciences Holdings, Inc.

As you can clearly see from the Momentum Grade breakdown above, Maravai LifeSciences Holdings, Inc. is considered to have stronger momentum compared to Denali Therapeutics Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Maravai LifeSciences Holdings, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. Grades

In addition to Momentum, Value and Growth, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Denali Therapeutics Inc., Maravai LifeSciences Holdings or Inc. Stock?

Overall, Denali Therapeutics Inc. stock has a Value Score of , Growth Score of and Momentum Score of 75.

Maravai LifeSciences Holdings, Inc. stock has a Value Score of 14, Growth Score of 8 and Momentum Score of 96.

Comparing Denali Therapeutics Inc., Maravai LifeSciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.